MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
NeoGenomics Net Debt 2011-2026 | NEO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt NeoGenomics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -23.3 M | 201 M | 279 M | 223 M | -55.6 M | -76.2 M | 90.9 M | 82.1 M | 83.4 M | 38.4 M | -25.2 M | 3.33 M | 11.9 M | 5.98 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 279 M | -76.2 M | 59.9 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-76 M | $ 34.65 | 1.73 % | $ 361 M |  China |
 |
Brainsway Ltd.
BWAY
|
-6.88 M | $ 23.45 | 0.3 % | $ 99.4 M |  Israel |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
-2.64 M | $ 1.24 | -4.63 % | $ 1.58 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
-108 M | $ 39.81 | 1.05 % | $ 1.11 B | USA |
 |
Co-Diagnostics
CODX
|
-11.9 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
13.6 B | $ 219.86 | 0.45 % | $ 161 B | USA |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | China |
 |
Exact Sciences Corporation
EXAS
|
-560 M | $ 102.48 | 0.13 % | $ 19 B | USA |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
-487 M | $ 73.19 | 0.21 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
-48 M | $ 20.74 | 0.92 % | $ 1.12 B | USA |
 |
Celcuity
CELC
|
82.8 M | $ 108.88 | -0.49 % | $ 4.3 B | USA |
 |
Guardant Health
GH
|
646 M | $ 115.53 | 1.31 % | $ 14.2 B | USA |
 |
DarioHealth Corp.
DRIO
|
-12.1 M | $ 10.46 | 4.39 % | $ 297 M | Israel |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 26.18 | -0.08 % | $ 792 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
IDEXX Laboratories
IDXX
|
183 M | $ 631.02 | -5.88 % | $ 52 B | USA |
 |
Illumina
ILMN
|
-494 M | $ 141.12 | -2.55 % | $ 22.4 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B |  Niderland |
 |
Lantheus Holdings
LNTH
|
-346 M | $ 66.99 | 0.1 % | $ 4.64 B | USA |
 |
IQVIA Holdings
IQV
|
11.2 B | $ 230.21 | 0.03 % | $ 41.7 B | USA |
 |
Medpace Holdings
MEDP
|
-520 M | $ 588.24 | 0.99 % | $ 18.2 B | USA |
 |
Charles River Laboratories International
CRL
|
2.1 B | $ 210.96 | 0.18 % | $ 10.8 B | USA |
 |
National Research Corporation
NRC
|
30.1 M | $ 21.65 | 6.44 % | $ 531 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 182.93 | -2.16 % | $ 20.3 B | USA |
|
Biodesix
BDSX
|
14.5 M | $ 9.13 | -10.28 % | $ 1.18 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 28.76 | 0.19 % | $ 20 B | Niderland |
 |
Precipio
PRPO
|
-1.18 M | $ 25.0 | 1.92 % | $ 32.4 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4 B | $ 267.03 | -1.65 % | $ 22.4 B | USA |
 |
Personalis
PSNL
|
-48.8 M | $ 9.32 | -0.53 % | $ 552 M | USA |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 177.42 | -1.57 % | $ 14.6 B |  Irlanda |
 |
Agilent Technologies
A
|
1.24 B | $ 133.81 | -0.04 % | $ 40.7 B | USA |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.38 | 0.18 % | $ 5.47 M | USA |
 |
OpGen
OPGN
|
711 K | - | -16.95 % | $ 1.54 M | USA |
 |
Bioventus
BVS
|
334 M | $ 8.11 | 2.27 % | $ 508 M | USA |